📰 Randomized Controlled Phase News
Page 2 - Randomized Controlled Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Randomized Controlled Phase. Real-time updates on events, politics, business and more.
February 18, 2021
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycos...
February 18, 2021
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safetyLugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the u...
February 18, 2021
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 - Helsinn, a Swiss pharmaceutical group focused
January 25, 2021
European Commission Approves AbbVies RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RI...